Technical Analysis for CRBU - Caribou Biosciences, Inc.

Grade Last Price % Change Price Change
D 2.21 12.76% 0.25
CRBU closed up 12.76 percent on Friday, November 1, 2024, on 2.04 times normal volume.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up

Date Alert Name Type % Chg
MACD Bullish Centerline Cross Bullish 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
BB Squeeze Ended Range Expansion 0.00%
Above Upper BB Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
20 DMA Support Bullish 12.76%
50 DMA Support Bullish 12.76%
Bollinger Band Squeeze Range Contraction 12.76%

   Recent Intraday Alerts

Alert Time
Possible Pocket Pivot about 19 hours ago
Up 2 ATRs about 22 hours ago
2x Volume Pace about 23 hours ago
1.5x Volume Pace about 23 hours ago
60 Minute Opening Range Breakout about 23 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Caribou Biosciences, Inc. Description

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Solid Tumors Cancer Immunotherapy Cell Therapy Cell Biology Leukemia Multiple Myeloma Breakthrough Therapy Hematologic Malignancies Chimeric Antigen Receptor T Cell T Cells CD19 Refractory Acute Myeloid Leukemia Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia

Is CRBU a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.33
52 Week Low 1.5
Average Volume 934,598
200-Day Moving Average 3.45
50-Day Moving Average 1.96
20-Day Moving Average 1.93
10-Day Moving Average 1.94
Average True Range 0.14
RSI (14) 64.16
ADX 13.18
+DI 30.99
-DI 14.16
Chandelier Exit (Long, 3 ATRs) 1.81
Chandelier Exit (Short, 3 ATRs) 2.17
Upper Bollinger Bands 2.12
Lower Bollinger Band 1.73
Percent B (%b) 1.24
BandWidth 20.03
MACD Line 0.02
MACD Signal Line -0.01
MACD Histogram 0.0251
Fundamentals Value
Market Cap 195.43 Million
Num Shares 88.4 Million
EPS -1.43
Price-to-Earnings (P/E) Ratio -1.55
Price-to-Sales 17.71
Price-to-Book 1.51
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.62
Resistance 3 (R3) 2.58 2.41 2.55
Resistance 2 (R2) 2.41 2.31 2.43 2.52
Resistance 1 (R1) 2.31 2.24 2.36 2.35 2.50
Pivot Point 2.14 2.14 2.17 2.16 2.14
Support 1 (S1) 2.04 2.04 2.09 2.08 1.92
Support 2 (S2) 1.87 1.97 1.89 1.90
Support 3 (S3) 1.77 1.87 1.87
Support 4 (S4) 1.81